Gemina Labs Announces Addition to its IP Portfolio

Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) revealed today the licensing of a pioneering biosensing architecture from the University of British Columbia. This marks a significant step in their research collaboration initiated in 2021. The deal enhances Gemina's technological repository with point-of-care biosensor chips, facilitating the detection of various biomolecules cost-effectively.

The licensed technology, underpinning a new patent application, aims to scale up the production of affordable, single-use molecular assays. This innovation could greatly improve the diagnostic accuracy of infections like tuberculosis, aligning with the WHO's urgency for new diagnostic tools to combat the disease's global impact.

Gemina's CTO, Robert Greene, highlighted the success of the partnership with UBC, underlining the synergy between industrial and academic research efforts. This collaboration, he notes, significantly boosts Gemina's intellectual property and advances its mission to develop accessible diagnostic solutions.